HOME  >  Online journal

Vol.61 No.2 contents

Japanese/English

Full Text of PDF (293K) Article in Japanese

- Review Article -

Classification and Treatment of Oligometastatic Disease in Non-Small-Cell Lung Cancer

Kiichiro Ninomiya¹, Yusuke Okuma², Noriyuki Ebi³, Keiju Aokage⁴, Yuko Oya⁵, Tomohiro Sakamoto⁶, Toshiyuki Kozuki⁷, Kaname Nosaki⁸, Katsuyuki Shirai⁹, Tetsuo Nonaka¹⁰, Miyako Satouchi¹¹, Hitoshi Ishikawa¹², Katsuyuki Hotta¹³, Yuichi Takiguchi^14
1Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan, ²Department of Thoracic Oncology, National Cancer Center Hospital, Japan, ³Department of Respiratory Oncology, Iizuka Hospital, Japan, ⁴Department of Thoracic Surgery, National Cancer Center Hospital East, Japan, ⁵Department of Thoracic Oncology, Aichi Cancer Center Hospital, Japan, ⁶Division of Respiratory Medicine and Rheumatology, Department of Multidisciplinary Internal Medicine, Tottori University, Japan, ⁷Department of Thoracic Oncology and Medicine, National Hospital Organization Shikoku Cancer Center, Japan, ⁸Department of Thoracic Oncology, National Cancer Center Hospital East, Japan, ⁹Department of Radiology, Jichi Medical University Hospital, Japan, ¹⁰Department of Radiation Oncology, Japanese Red Cross Medical Center, Japan, ¹¹Department of Thoracic Oncology, Hyogo Cancer Center, Japan, ¹²QST Hospital, Quantum Medical Science Directorate, National Institute for Quantum and Radiological Sciences and Technology, Japan, ¹³Center for Clinical Oncology, Okayama University Hospital, Japan, ¹⁴Department of Medical Oncology, Chiba University Hospital, Japan

---

The standard treatment for non-small-cell lung cancer (NSCLC) with distant metastases is pharmacotherapy, and the survival benefit of additional localized therapy has not been clarified. However, in cases of oligometastatic disease in which metastatic lesions are limited, a long-term prognosis has been observed with localized therapy. In recent years, several randomized controlled trials have reported the effects of additional localized therapy for oligometastatic disease. These trials have targeted cases of synchronous oligometastatic disease, and all have tended to show the extension of the survival period. Treatment of NSCLC is diversifying due to the advent of novel strategies, such as targeted therapy, immune checkpoint inhibitors, and radiotherapeutic technology. Localized therapy for oligometastatic disease might be a new treatment strategy, although the disadvantages of its invasiveness and the risks associated with discontinuation of pharmacotherapy need to be considered.
key words: Oligometastatic disease, Non-small cell lung cancer, Localized therapy

Received: November 11, 2020
Accepted: January 2, 2021

JJLC 61 (2): 95-99, 2021